Vir Biotechnology, Inc. Financing Cash Flow
Vir Biotechnology, Inc. (VIR) reported Financing Cash Flow of $240.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- Vir Biotechnology, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $78.38M, a 3730.69% increase year-over-year.
- Vir Biotechnology, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $162.52M, a 27077.76% increase year-over-year.
- Vir Biotechnology, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.04M, a 17.74% decline year-over-year.
- Vir Biotechnology, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $102.00K, a 229.03% increase year-over-year.
- Vir Biotechnology, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $3.79M, a 13.74% decline from fiscal 2024.
- Vir Biotechnology, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $4.39M, a 41.34% decline from fiscal 2023.
- Vir Biotechnology, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $7.48M, a 78.48% decline from fiscal 2022.
- Vir Biotechnology, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $34.76M, a 65.35% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $78.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $240.90M 10-Q · filed 2026-08-05 | $241.94M derived: sum of 3 quarters · filed 2026-08-05 | $242.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $162.52M 10-Q · filed 2026-05-07 | $163.56M derived: sum of 2 quarters · filed 2026-05-07 | $163.66M derived: sum of 3 quarters · filed 2026-05-07 | $165.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.14M derived: sum of 2 quarters · filed 2026-02-23 | $3.19M derived: sum of 3 quarters · filed 2026-08-05 | $3.79M 10-K · filed 2026-02-23 |
| 2025-09-30 | $102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.15M derived: sum of 2 quarters · filed 2026-08-05 | $2.75M 10-Q · filed 2025-11-05 | $4.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.64M 10-Q · filed 2026-08-05 | $3.91M derived: sum of 3 quarters · filed 2026-08-05 | $3.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $598.00K 10-Q · filed 2026-05-07 | $1.86M derived: sum of 2 quarters · filed 2026-05-07 | $1.89M derived: sum of 3 quarters · filed 2026-05-07 | $4.83M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.29M derived: sum of 2 quarters · filed 2026-02-23 | $4.24M derived: sum of 3 quarters · filed 2026-02-23 | $4.39M 10-K · filed 2026-02-23 |
| 2024-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.97M derived: sum of 2 quarters · filed 2025-11-05 | $3.13M 10-Q · filed 2025-11-05 | $4.80M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $2.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $3.09M 10-Q · filed 2025-08-06 | $4.77M derived: sum of 3 quarters · filed 2026-02-23 | $5.05M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $152.00K 10-Q · filed 2025-05-08 | $1.83M derived: sum of 2 quarters · filed 2026-02-23 | $2.11M derived: sum of 3 quarters · filed 2026-02-23 | $5.29M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.96M derived: sum of 2 quarters · filed 2026-02-23 | $5.14M derived: sum of 3 quarters · filed 2026-02-23 | $7.48M 10-K · filed 2026-02-23 |
| 2023-09-30 | $277.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $3.46M derived: sum of 2 quarters · filed 2024-11-04 | $5.80M 10-Q · filed 2024-11-04 | $7.81M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $5.52M 10-Q · filed 2024-08-01 | $7.53M derived: sum of 3 quarters · filed 2025-02-27 | $9.52M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.34M 10-Q · filed 2024-05-03 | $4.36M derived: sum of 2 quarters · filed 2025-02-27 | $6.34M derived: sum of 3 quarters · filed 2025-02-27 | $9.42M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.00M derived: sum of 2 quarters · filed 2025-02-27 | $7.08M derived: sum of 3 quarters · filed 2025-02-27 | $34.76M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $5.07M derived: sum of 2 quarters · filed 2023-11-03 | $32.75M 10-Q · filed 2023-11-03 | $38.42M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $3.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $30.77M 10-Q · filed 2023-08-04 | $36.44M derived: sum of 3 quarters · filed 2024-02-26 | $40.06M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $27.68M 10-Q · filed 2023-05-08 | $33.35M derived: sum of 2 quarters · filed 2024-02-26 | $36.98M derived: sum of 3 quarters · filed 2024-02-26 | $40.51M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $9.30M derived: sum of 2 quarters · filed 2024-02-26 | $12.83M derived: sum of 3 quarters · filed 2024-02-26 | $100.33M 10-K · filed 2024-02-26 |
| 2021-09-30 | $3.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $7.16M derived: sum of 2 quarters · filed 2022-11-03 | $94.66M 10-Q · filed 2022-11-03 | $94.40M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $3.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $91.03M 10-Q · filed 2022-08-09 | $90.77M derived: sum of 3 quarters · filed 2023-02-28 | $415.08M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $87.50M 10-Q · filed 2022-05-05 | $87.24M derived: sum of 2 quarters · filed 2023-02-28 | $411.55M derived: sum of 3 quarters · filed 2023-02-28 | $616.89M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $324.05M derived: sum of 2 quarters · filed 2023-02-28 | $529.39M derived: sum of 3 quarters · filed 2023-02-28 | $529.47M 10-K · filed 2023-02-28 |
| 2020-09-30 | $324.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $529.65M derived: sum of 2 quarters · filed 2021-11-04 | $529.73M 10-Q · filed 2021-11-04 | $659.83M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $205.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $205.43M 10-Q · filed 2021-08-05 | $335.52M derived: sum of 3 quarters · filed 2022-02-28 | $337.26M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $85.00K 10-Q · filed 2021-05-06 | $130.19M derived: sum of 2 quarters · filed 2022-02-28 | $131.92M derived: sum of 3 quarters · filed 2022-02-28 | $131.92M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $130.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $131.83M derived: sum of 2 quarters · filed 2022-02-28 | $131.84M derived: sum of 3 quarters · filed 2022-02-28 | $449.24M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $1.74M derived: sum of 2 quarters · filed 2020-11-10 | $319.14M 10-Q · filed 2020-11-10 | $329.58M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $317.41M 10-Q · filed 2020-08-11 | $327.85M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $317.41M 10-Q · filed 2020-05-12 | $327.85M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $10.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $24.98M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $14.54M 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | $271.18M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |